CAR-T cell therapy deals reach this total value at Phase 2

CAR-T cell therapy remains a high-value modality despite manufacturing complexity. Deal structures reflect the transformative potential of cell therapy, with substantial milestone payments tied to manufacturing scale-up, regulatory approval, and commercial success across multiple indications.

Based on analysis of 600+ biopharma licensing deals from 2020-2026